Not provided
Not provided
Not provided
Not provided
Not provided
bankruptcy app owner
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Elisabeth-TweeSteden Ziekenhuis | OTHER |
| Radboud University Medical Center | OTHER |
Not provided
Not provided
Not provided
Not provided
A multicenter, randomized controlled trial with an embedded pilot and qualitative component to investigate the effects of the Nori Health app.
RATIONALE Inflammatory bowel disease (IBD) is an umbrella term used to describe diseases that involve chronic inflammation of the gastrointestinal tract. Although progress in treatment has been made over the past two decades, IBD continues to profoundly affect patients' quality of life. Since patients with IBD have to deal with their disease's complex and unpredictable nature 24 hours a day, it is important that they have access to self-management support outside the hospital. Nori Health aims to provide this support with an app that consists of an artificial intelligence-driven chatbot and 6-week education program.
OBJECTIVES
The primary objective is to investigate whether use of the Nori Health app improves the level of patient activation for self-management in patients with IBD by comparing an intervention and (waiting-list) control group at 6 weeks after randomization. Secondary objectives are:
STUDY DESIGN A multicenter, randomized controlled trial with an embedded pilot and qualitative component.
STUDY POPULATION
Patients with IBD are eligible for participation if they:
Excluded are those with cognitive impairments or who are already familiar with use of the Nori Health app.
STUDY INTERVENTION Participants are randomized in a 1:1 ratio to the intervention or control group. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention. Standard IBD care continues unchanged. After study completion, participants in the control group also receive access to the Nori Health app for a 6-month period.
STUDY PARAMETERS The level of patient activation for self-management is assessed using the patient activation measure. The IBD control questionnaire and EQ-5D are used to assess respectively the level of disease control and quality of life. Healthcare utilization is assessed with 5 close-ended questions. System data is used to assess intervention fidelity. Experiences of patients with IBD with use of the Nori Health app and their views on its pros and cons are explored by performing individual, semi-structured, telephonic interviews.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | Use of the Nori Health app during the study period, standard care |
|
| Control group | No Intervention | No use of the Nori Health app during the study period, standard care |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The Nori Health app | Other | The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Activation Measure (PAM) | Measure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome). | 6 weeks follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Patient Activation Measure (PAM) | Measure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome). | 12 and 20 weeks follow-up |
| Inflammatory Bowel Disease (IBD)-control questionnaire |
| Measure | Description | Time Frame |
|---|---|---|
| Interviews | Experiences of patients with IBD with use of the Nori Health app and their views on its pros and cons. | 6-20 weeks follow-up |
Patients with IBD are eligible for participation if they:
Excluded are those with cognitive impairments or who are already familiar with use of the Nori Health app.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Radboudumc | Nijmegen | Netherlands | ||||
| Elisabeth-TweeSteden Ziekenhuis |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40243391 | Derived | Tiles-Sar N, Neuser J, de Sordi D, Baltes A, Preiss JC, Moser G, Timmer A. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2025 Apr 17;4(4):CD006913. doi: 10.1002/14651858.CD006913.pub3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Randomized controlled trial
Not provided
Not provided
Not provided
Not provided
|
Measure of disease control. Scale from 0 to 16, higher scores mean a higher level of disease control (=better outcome). |
| 6, 12 and 20 weeks follow-up |
| EuroQol-5 dimension questionnaire (EQ-5D) | Measure of quality of life. Scale from 0 to 100, higher scores mean a higher quality of life (=better outcome). | 6, 12 and 20 weeks follow-up |
| Healthcare utilization | Brief questionnaire with 5 close-ended questions on healthcare utilizatio, using a nominal scale (e.g., yes/no). | 6, 12 and 20 weeks follow-up |
| Tilburg |
| Netherlands |
| D007410 | Intestinal Diseases |
| D003092 | Colitis |
| D003108 | Colonic Diseases |